Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteglobeimmune.com
CategoryBioTech
Phone303-625-2700
Employees
Founded1995

Offices

Louisville, USA
1450 Infinite Drive
Louisville, CO, 80027
USA

People

CEO
Board of Directors
Board of Directors

Funding

TOTAL $42.4M
FUNDING TOTAL $42.4M
Venture Round, 5/2009
$13M
Series E, 1/2010
Generali Financial Holding
$17.5M
Grant, 9/2013
$4M
Venture Round, 2/2014
$7.5M
Venture Round, 3/2014
$392k
DEBT TOTAL $2.56M
Debt, 3/2009
$2.56M

Tags

GlobeImmune

GlobeImmune, Inc. operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune, Inc. was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.

Recent Milestones

Videos

Screenshots

GlobeImmune screenshot
Above: Home Page
Uploaded: 1/20/10

Sources

  1. SEC (sec.gov) [edit]
  2. SEC (sec.gov) [edit]
  3. GlobeImmune Raises $17.5M (finsmes.com) [edit]
  4. GlobeImmune Awarded $4 Million NIH Grant to Develop Tarmogens for the Treatment of Tuberculosis (reuters.com) [edit]
  5. SEC (sec.gov) [edit]
  6. SEC (sec.gov) [edit]
Edit This Page
Last Edited 3/13/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy